|
2.4 ETIOLOGIE - PORTABLES, ONDES E-M
|
|
|
Scientists Sign Petition Warning about EMF [Science-Based Medicine]
|
|
|
|
|
|
Even for an organization dedicated to assessing the risk of radiofrequency technology, it is advisable not to overstate the science, lest you lose credibility and may actually hurt the cause you are fighting for. I think this will be the ultimate result of this petition.
|
|
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
|
U.S. proposes stricter curbs on e-cigarette sales [Reuters]
|
|
|
|
|
|
The proposal would allow traditional retailers such as convenience stores to sell tobacco, mint and menthol e-cigarettes, which the FDA says are more popular among adults than minors. But other flavors could only be sold in stores or online when strong age-verification protocols are in place.
|
|
|
|
|
|
|
4.1 DÉP., DIAG. & PRONO. - PROSTATE
|
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
Genetron Health Adds Prospective Data on Early Detection of Viral Liver Cancer in Blood [Genome Web]
|
|
|
|
|
|
In the study, published this Monday in the Proceedings of the National Academy of Sciences, investigators from the Chinese Academy of Medical Sciences working with Genetron followed more than 300 individuals with hepatitis B who had normal liver ultrasonography and serum alpha fetoprotein (AFP) levels to see if the company's test could identify those who would go on to be diagnosed with hepatocellular carcinoma (HCC).
|
|
|
|
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
|
Cancer's 'internal wiring' predicts relapse risk [BBC News]
|
|
|
|
|
|
The study shows that breast cancer is 11 separate diseases that each has a different risk of coming back. The hope is that the findings, in the journal Nature, could identify people needing closer monitoring and reassure others at low risk of recurrence.
|
|
|
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
Clinical Analytics Platform TriNetX Raises $40M to Speed Drug Trials [Xconomy]
|
|
|
|
|
|
The company’s analytics platform helps pharma companies detail the many aspects of a clinical trial—from choosing hospital locations with adequate populations of patients to managing what age ranges and other demographic variables to include in the studies—to cut down on delayed studies due to a redesign or amendment.
|
|
|
|
|
|
|
|
5.2 PHARMA
|
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
5.9.8 AACR - PHARMA
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.9 CONTROVERSES
|
|
|